Pork producers now have a new tool in their battle against porcine reproductive and respiratory syndrome. MJ Biologics and the University of Minnesota have teamed up to develop Selectigen MJPRRS-- a new inactivated subunit PRRS vaccine.

By breaking the genetic code of the PRRS virus, MJPRRS technology allows the production of autogenous vaccines tailored to each unique swine production system. The new technology utilizes an innovative method of classifying PRRS viruses based on their immunological properties allowing for creation of custom vaccines.

In pregnant sow control studies conducted by independent veterinarians and the University of Minnesota, the MJPRRS vaccine provided excellent cross-protection against heterologous PRRS strains.

“By using the vaccine in herds with a history of PRRS virus, we have been able to prevent prenatal losses while stabilizing the herds and simultaneously protecting the sow population against clinical disease outbreaks from ‘new’ virus strains entering the herd,” says Paul Armbrecht, DVM, Lake City Veterinary Service, Lake City, Iowa.

Many veterinarians and producers have experienced the value of MJPRRS vaccine. “MJPRRS technology appears to be one of the biggest breakthroughs in disease control across the swine industry in the last 10 years,” according to Mark Fitzsimmons, DVM. “Finally we have some light at the end of the tunnel in controlling and preventing this devastating disease.”

MJ Biologics has teamed with USDA-licensed companies to produce MJPRRS autogenous vaccine, which is now available through licensed veterinarians. For more information, contact MJ Biologics at (507) 385-0299 or visit the company’s Web site at www.mjbio.com.

Source: MJ Biologicals